Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Multicenter, Open-label, Comparative, Efficacy Study of Pegasys Plus Copegus in Treatment-naive Latino Patients With Chronic Hepatitis C-genotype 1, as Compared to Treatment-naive Non- Latino Caucasian Patients With Chronic Hepatitis C-genotype 1

Next Previous
X
Search
Trial Profile

A Prospective, Multicenter, Open-label, Comparative, Efficacy Study of Pegasys Plus Copegus in Treatment-naive Latino Patients With Chronic Hepatitis C-genotype 1, as Compared to Treatment-naive Non- Latino Caucasian Patients With Chronic Hepatitis C-genotype 1

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms LATINO

    • Most Recent Events

    • 01 Jun 2010 Actual end date changed from Mar 2006 to Feb 2008 as reported by ClinicalTrials.gov.
    • 14 Jan 2009 Primary endpoint 'Sustained virological response rate' has been met.
    • 14 Jan 2009 Results published in the New England Journal of Medicine, according to 1020878.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top